Biosimilar uptake drivers will apply to all brands, PBAC confirms

Biosimilar ‘uptake drivers’ that encourage prescribing of biosimilars over originator biologics will be applied universally and not just to the brand that makes an application for them, the federal government has confirmed. The Pharmaceutical Benefits Advisory Committee (PBAC) has set out its position on  uptake measures such as lower authority levels in newly-released documents covering the ...

Already a member?

Login to keep reading.

© 2022 the limbic